George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 Apr 11. doi: 10.1007/s41669-024-00483-w
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Wang Z, Zellers S, Whipp AM, Heinonen-Guzejev M, Foraster M, Julvez J, van Kamp I, Kaprio J. The effect of environment on depressive symptoms in late adolescence and early adulthood: an exposome-wide association study and twin modeling. Nat Mental Health. 2023 Sep 25. doi: https://doi.org/10.1038/s44220-023-00124-x
de Sousa Maciel I, Piironen AK, Afonin AM, Ivanova M, Alatalo A, Jadhav KK, Julvez J, Foraster M, van Kamp I, Kanninen KM. Plasma proteomics discovery of mental health risk biomarkers in adolescents. Nat Mental Health. 2023 Aug;1:596-605. doi: 10.1038/s44220-023-00103-2
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4